Stratifying for Distant Brain Failure, Whole-brain Radiotherapy Beneficial
the Cancer Therapy Advisor take:
Stratification for early distant brain failure (DBF) and salvage whole-brain radiotherapy (WBRT) in patients initially treated with stereotactic radiosurgery (SRS) may be useful for treatment decision-making for patients with brain metastases, according to an article published online in the journal Cancer.
The authors analyzed the medical records of 270 patients with brain metastases who were treated with SRS from 2003 to 2012.
Results showed significant predictors of early DBF included no prior WBRT, a total lesion volume less than 1.3 cm3, primary breast cancer or malignant melanoma histology, and multiple metastases (≥2). One point was ascribed to each of these identified factors because of their similar hazard ratios.
A score of 0 to 1 indicated low risk; a score of 2 was determined to indicate intermediate risk, while a score of 3 to 4 indicated high risk. The 6-month cumulative incidences of DBF for these three groups were 16.6%, 28.8%, and 54.4%, respectively (P<0.001).
Furthermore, the 6-month cumulative incidence of salvage WBRT in patients without prior WBRT was determined to be 2%, 17.7%, and 25.7%, respectively for the three cohorts (P<0.001).
Stratification for early distant brain failure and salvage whole-brain radiotherapy may be useful for brain metastases.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma